Business Context and Reporting Period
This Form 8-K filing by U.S. Gold Corp. (USAU) covers events occurring on July 23, 2019, and July 25, 2019. The company is incorporated in Nevada and trades on the Nasdaq Capital Market. The report addresses governance issues related to the composition of the Audit Committee and compliance with Nasdaq listing standards.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
- Audit Committee Independence: The Company determined that Ryan K. Zinke, appointed to replace James D. Davidson (who resigned July 1, 2019), did not meet the independence standards required by Rule 10A-3 of the Securities Exchange Act of 1934 and Nasdaq Listing Rule 5605(2)(A).
- Nasdaq Noncompliance: On July 16, 2019, the Company notified Nasdaq of its failure to maintain three independent audit committee members. On July 25, 2019, Nasdaq confirmed this noncompliance.
- Resignation: Effective July 23, 2019, Ryan K. Zinke resigned from the Audit Committee due to the independence determination. He remains an independent member of the Board of Directors.
Outlook, Risks, and Contingencies
Cure Period: The Company intends to utilize the cure period provided by Nasdaq Listing Rule 5605(c)(4). Compliance with the listing requirement is required by the earlier of the Company's next annual shareholders' meeting or June 30, 2020. If the next annual meeting is held before December 27, 2019, compliance must be achieved by December 27, 2019.
Risk: Failure to cure the deficiency within the specified timeframe could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current composition of the Audit Committee to ensure it meets the three independent member requirement.
- Confirm the date of the next annual shareholders' meeting to determine the exact deadline for curing the listing deficiency.
- Review subsequent filings to confirm if a new independent director has been appointed to the Audit Committee.
- Check for any further correspondence from Nasdaq regarding the status of the cure period.